- In March 2025, Zydus Lifesciences announced that it has received final approval from the U.S. Food and Drug Administration (USFDA) to manufacture and market Ketoconazole Shampoo, 2%. This generic antifungal medication is used to treat dandruff, fungal infections, and various other skin conditions, the company stated
- In March 2025, Chinese researchers reported in Nature the discovery of mandimycin, a novel glycosylated polyene antifungal that successfully kills drug-resistant fungi, including Candida auris, by targeting fungal lipid membranes—showing promising results in test tubes and animal models
- In June 2024, biotechnology company Biocon Ltd announced that it has received approval from the U.S. Food and Drug Administration (US FDA) for its complex, vertically integrated injectable product, Micafungin, in 50mg and 100mg vial strengths
- In March 2023, the U.S. FDA approved rezafungin (Rezzayo), a long-acting echinocandin, for treating candidemia and invasive candidiasis in adults. It offers once-weekly intravenous dosing and non-inferiority to caspofungin in Phase 3 trials
- In May 2022, Shionogi & Co., Ltd. and F2G Ltd. announced a strategic partnership to develop and commercialize the novel antifungal agent olorofim across Europe and Asia. Developed by F2G, olorofim is an innovative oral therapy designed to treat invasive aspergillosis (IA) and other rare mold infections
